These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 580761)

  • 1. The renal elimination of rifampicin as a function of the oral dose. A convenient way to assess relative bioavailability.
    Brechbühler S; Fluehler H; Riess W; Theobald W
    Arzneimittelforschung; 1978; 28(3):480-3. PubMed ID: 580761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of rifampicin caplets (600 mg and 450 mg) in healthy Indonesian subjects.
    Ganiswarna SG; Wilmana PF; Setiabudy R; Ringoringo VS
    Int J Clin Pharmacol Ther Toxicol; 1986 Feb; 24(2):60-4. PubMed ID: 3957493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
    McIlleron H; Gabriels G; Smith PJ; Fourie PB; Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S329-35; discussion S351-2. PubMed ID: 10593713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
    Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Urinary excretion of rifampicin in kidney failure when administered alone or together with isoniazid].
    Titarenko OT; Vakhmistrova TI; Perova TL
    Antibiotiki; 1983 Sep; 28(9):698-702. PubMed ID: 6638984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
    Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and urine concentrations of rifampicin administered by intravenous infusion in man.
    Acocella G; Bonollo L; Mainardi M; Margaroli P; Tenconi LT
    Arzneimittelforschung; 1977; 27(6):1221-6. PubMed ID: 578447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The pharmacokinetics of rifampicin in the intermittent treatment of patients with pulmonary tuberculosis. 1. Excretion of rifampicin in the urine].
    Winsel K; Eule H; Werner E; Iwainsky H
    Pharmazie; 1985 Apr; 40(4):253-6. PubMed ID: 4011658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiological assay versus spectrophotometry for determination of rifampicin in urine.
    George J; Bhatia VN; Balakrishnan S
    Indian J Lepr; 1988 Jan; 60(1):47-52. PubMed ID: 3060546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal elimination of magnesium as a parameter of bioavailability of oral magnesium therapy.
    Kuhn I; Jost V; Wieckhorst G; Theiss U; Lücker PW
    Methods Find Exp Clin Pharmacol; 1992 May; 14(4):269-72. PubMed ID: 1507928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioavailability of rifampicin capsules.
    Buniva G; Pagani V; Carozzi A
    Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):404-9. PubMed ID: 6688798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bioavailability of 2 different rifampicin preparations].
    Aronne Benach MT; Naranjo Cascante G
    Rev Clin Esp; 1980 Oct; 159(1):43-6. PubMed ID: 7008102
    [No Abstract]   [Full Text] [Related]  

  • 18. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms.
    Agrawal S; Panchagnula R
    Biopharm Drug Dispos; 2005 Nov; 26(8):321-34. PubMed ID: 16059874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary excretion of rifampicin and its metabolites as an index of rifampicin blood levels.
    Wardell WM; McQueen EG
    N Z Med J; 1970 Dec; 72(463):393-6. PubMed ID: 5278257
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.